MEI Pharma, Inc. stock is down -13.29% since 30 days ago. The next earnings date is Feb 8, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 11 December’s closed higher than November.
MEI Pharma, Inc. focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trials for patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex in Phase I clinical trial for human epidermal growth factor receptor 2 negative breast cancer.